You are here:

Cannabis and cannabinoids for medicinal purposes: Reviewing the evidence

posted 31/10/2016

publication National Drug and Alcohol Research Centre (NDARC)

Date Commenced:
10/2016

Expected Date of Completion:
12/2017
Project Supporters:

Funding was received from the Health Products Regulation Group, Commonwealth Department of Health

Drug Type:
Cannabis


Project Members
Professor Louisa Degenhardt
Professor
Ph 02 9385 0333
l.degenhardt@unsw.edu.au

Professor Michael Farrell
Director
Ph EA Jemma Sale: 02 9385 0292 / j.sale@unsw.edu.au
michael.farrell@unsw.edu.au


Dr Suzanne Nielsen
Research Fellow
Ph 02 8936 1017
suzanne.nielsen@unsw.edu.au

Professor Jan Copeland
Director NCPIC

Dr Peter Gates
Research Officer
Project Main Description 

This project will review the evidence for the medicinal use of cannabis and cannabinoid products for a number of key medical conditions. We will examine the evidence base for delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in particular, alone or in combination, in the major conditions for which cannabinoids have been advocated with a focus on assessments in either RCTs or observational studies.

Project Collaborators External: 

Other investigators:

Professor Wayne Hall
University of Queensland

Professor Nicholas Buckley
University of Sydney

Dr Megan Weier
University of Queensland

Collaborators:

Dr Bridin Murnion
University of Sydney

Professor John Pollard
University of Sydney

Professor Meera Agar
UTS

Associate Professor Melanie Lovell
University of Sydney

Rationale 

From October 31 2016, locally-cultivated and manufactured cannabis and cannabinoid products will be able to be provided under a system of regulation overseen by the Commonwealth Department of Health (see https://www.tga.gov.au/medicinal-cannabis-products-overview-regulation; and https://www.tga.gov.au/access-medicinal-cannabis-products-questions-and-answers). A small number of commercial cannabis-derived and synthetic products are available globally, but it is likely that in Australia there will be an increase in the coming years in availability of cannabinoid products derived from locally-grown plants. This will include both extracts and oils, which will contain defined levels of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

The purpose of this project is to provide a shared point of reference for individual clinicians, State and Territory health departments and the Commonwealth Department of Health. For clinicians, it will inform decisions about whether to seek permission from government to prescribe medicinal cannabis products; and it will inform governments in making decisions about whether such authorisations should be granted.

To support decision making, draft guidance documents will be developed that summarise the evidence base for cannabinoid products for particular conditions.

Through a process to be managed and coordinated by states and territories and the Commonwealth, clinical experts will review the draft guidance documents, including the provision of commentary on the appropriate place in therapy of the cannabinoid-based products relative to alternative pharmacological (and where appropriate, non-pharmacological) interventions.

Aims 

To complete systematic reviews to inform policy and clinical practice in relation to the use of cannabis and cannabinoids for medicinal purposes.

Design and Method 

This project will involve the conduct of a staged process of review of the evidence for the medical use of cannabis and cannabinoid products for a number of key medical conditions. 

Activity 1: Review of critical reviews of evidence and of clinical guidance documents

The first stage will involve a “review of reviews” approach which will summarise the existing evidence based upon the review conclusions. It will focus upon Cochrane and other key reviews that have been recently completed. Other reviews will be searched for in the peer-reviewed literature.

In this piece of work, the focus will be centred initially upon the following conditions:

Epilepsy (children and adults)
Palliative care (for control of pain and improving appetite)
Pain (including cancer or AIDS related, neuropathic pain and chronic non-cancer pain)
Nausea and vomiting (cancer or AIDS related)
Multiple sclerosis

Activity 2: Development of draft clinical guidance

A “draft clinical guidance document” for the use of cannabinoids will be drafted for each condition described above in activity 1. These drafts will be reviewed and further developed by Australian clinical experts through a process separately managed and coordinated by the Commonwealth and States and Territories.

Activity 3: Systematic review and synthesis of evidence

This stage will use a standard systematic review approach to evidence. In undertaking these reviews, the results of the literature search will be used to make decisions about whether a full new systematic review and meta-analysis is warranted, based upon the number of studies identified that have not been included in previous reviews, and extent to which they or studies current underway could provide evidence that would change conclusions of earlier reviews.

Study-level details will be extracted from existing Cochrane and other systematic reviews, and additional RCT and observational-level evidence sought from systematic searches of the peer-reviewed literature, clinical trial websites and from contacting companies marketing cannabinoid products.

Progress/Update 

Reviews of reviews commenced in October 2016.

Output 

Published review of review protocols:

Cannabis and cannabinoids for medical purposes: a review of reviews for pain
Prospero registration number: CRD42016049475

Cannabis and cannabinoids for medical purposes: a review of reviews for epilepsy. PROSPERO registration number CRD42016050974
Cannabis and cannabinoids for medical purposes: a review of reviews for nausea and vomiting. PROSPERO registration number CRD42016050975

Cannabis and cannabinoids for medical purposes: a review of reviews for palliative care
PROSPERO registration number CRD42016051240

Cannabis and cannabinoids for medical purposes: a review of reviews for multiple sclerosis
PROSPERO registration number CRD42016051264

Project Research Area 
Treatment and Intervention
Drug policy
Drug Type 
Cannabis
Project Status 
Current
Programs 
Epidemiology and Data Linkage

get involved

If you are interested in what we do and would like to support our work, find out more ways to get involved.

Donate

get our book

Drugs: It’s just not worth it

Drugs: It’s just not worth it

Our 35-page book gives clear and easy to read facts and advice aimed at teenagers and young people.

£3.00

Buy Now